A randomized trial of Bacteroides fragilis 839 on preventing chemotherapy-induced myelosuppression and gastrointestinal adverse effects in breast cancer patients.

• DOI: 10.6133/apjcn.202403_33(1).0003
• Publication Date: 2024-03-01
• Authors: Ting Zeng; Yuhong Deng; Chu-Hui Lin; Xinxin Chen; Haixia Jia; Xiaowu Hu; Ting Xia; Yun Ling; Lehong Zhang; Tengfei Cao
• Keywords: Epirubicin; Gastrointestinal cancer; Bacteroides fragilis

To evaluate the potential benefits of Bacteroides fragilis 839 (BF839), a next-generation probiotics, in reducing myelosuppression and gastrointestinal toxicity associated with chemotherapy breast cancer patient.